NCT02028026

The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Massachusetts General Hospital · Academic / Other
• Sex: Female
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether vilazodone is more effective than citalopram for the treatment of anxious depression. We will use neuroimaging to see whether there are changes in the brains of patients receiving the drug vilazodone that are different from those of citalopram. These changes may show that vilazodone affects the brain differently than most other kinds of standard antidepressant medications.

Detailed description

This study proposes to utilize recent advances in magnetic resonance spectroscopy (MRS) techniques that permit reliable measurement of Glu in humans (9) to examine whether Vilazodone and citalopram exert differential effects on Glutamatergic neurotransmission in the ACC of anxious unipolar depressed patients. Functional connectivity as measured by Blood Oxygen Level Dependent (BOLD) MRI will be assessed to determine the relationship between the change in connectivity and the change in Glu levels with treatment. We also propose to examine, in an exploratory fashion, the relative effect of the two drugs on BOLD activation in the insula cortex.

Conditions

• Major Depressive Disorder
• Anxiety
• Comorbidity

Interventions

Type	Name	Description
DRUG	Vilazodone	10mg/day for 1 week, 20 mg/day for 1 week, and then 40 mg/day for 6 weeks.
DRUG	Citalopram	20 mg/day for 2 weeks and then 40 mg/day for 6 weeks

Timeline

• Start date: 2013-04-01
• Primary completion: 2015-02-01
• Completion: 2015-04-01
• First posted: 2014-01-06
• Last updated: 2016-11-08

Locations

1 site across 1 country: United States